Status:
ACTIVE_NOT_RECRUITING
French Version of the Banff Patellar Instability Instrument 2.0
Lead Sponsor:
Université de Sherbrooke
Conditions:
Patellar Instability
Eligibility:
All Genders
14+ years
Brief Summary
There are several treatment options for patellofemoral instability, but no established guidelines currently exist. An important step toward developing a consensus is to examine the influence of each i...
Detailed Description
To address our primary outcome described above, an analytical observational design has been chosen as no intervention is applied to the subjects under study. The prospective study will confirm our hyp...
Eligibility Criteria
Inclusion
- patient diagnosed with patellar instability with conservative or surgical treatment
- fluent in both spoken and written French
Exclusion
- Patients who are unable to understand and/or respond to the questionnaire
- Patients with another diagnosis or knee pathology under study (e.g., complex ligament tear of the knee, gonarthrosis)
- Patients with another diagnosis or lower limb pathology under study with secondary functional impairment (e.g., coxarthrosis)
- Patients with a change in the condition of the lower limb under study a. Exclusion from test-retest reliability calculations if symptoms of patellofemoral instability worsen or if there is new involvement of this lower limb between T0 and T1 b. Exclusion from response to change calculations if new involvement of the lower limb (e.g., ipsilateral lower limb trauma) occurs after treatment, i.e., between T0 and T2
- Patients answering fewer than 19 questions (out of 23 questions)
Key Trial Info
Start Date :
November 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06932900
Start Date
November 15 2021
End Date
August 1 2025
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIUSSS de l'Estrie-CHUS, 3001, 12e Ave Nord
Sherbrooke, Quebec, Canada, J1H5N4